Insufficient scRNA-seq data for expression of SPX at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 1695.60 | 89 / 89 | 86% | 18.71 | 773 / 901 |
brain | 99% | 2013.05 | 2619 / 2642 | 73% | 10.74 | 515 / 705 |
thymus | 98% | 1063.67 | 637 / 653 | 48% | 4.39 | 291 / 605 |
pancreas | 100% | 2196.29 | 328 / 328 | 6% | 0.20 | 10 / 178 |
heart | 68% | 326.16 | 585 / 861 | 0% | 0 | 0 / 0 |
liver | 35% | 103.25 | 79 / 226 | 26% | 1.05 | 105 / 406 |
adipose | 58% | 743.89 | 696 / 1204 | 0% | 0 | 0 / 0 |
breast | 45% | 506.13 | 206 / 459 | 6% | 0.31 | 64 / 1118 |
muscle | 36% | 182.11 | 289 / 803 | 0% | 0 | 0 / 0 |
ovary | 1% | 1.73 | 1 / 180 | 29% | 2.22 | 123 / 430 |
lung | 11% | 27.11 | 62 / 578 | 6% | 0.65 | 70 / 1155 |
skin | 9% | 31.97 | 168 / 1809 | 4% | 0.14 | 20 / 472 |
adrenal gland | 0% | 1.03 | 1 / 258 | 7% | 0.42 | 17 / 230 |
uterus | 0% | 0 | 0 / 170 | 7% | 0.46 | 34 / 459 |
esophagus | 4% | 10.96 | 59 / 1445 | 0% | 0 | 0 / 183 |
stomach | 1% | 3.51 | 4 / 359 | 1% | 1.08 | 3 / 286 |
intestine | 2% | 5.12 | 19 / 966 | 0% | 0 | 0 / 527 |
blood vessel | 1% | 4.62 | 20 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.03 | 1 / 80 |
peripheral blood | 1% | 1.31 | 6 / 929 | 0% | 0 | 0 / 0 |
bladder | 0% | 0 | 0 / 21 | 1% | 0.02 | 3 / 504 |
spleen | 0% | 0.73 | 1 / 241 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
prostate | 0% | 0 | 0 / 245 | 0% | 0 | 0 / 502 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0032099 | Biological process | negative regulation of appetite |
GO_0007165 | Biological process | signal transduction |
GO_1904306 | Biological process | positive regulation of gastro-intestinal system smooth muscle contraction |
GO_0010459 | Biological process | negative regulation of heart rate |
GO_0003084 | Biological process | positive regulation of systemic arterial blood pressure |
GO_0051930 | Biological process | regulation of sensory perception of pain |
GO_0044539 | Biological process | long-chain fatty acid import into cell |
GO_0035814 | Biological process | negative regulation of renal sodium excretion |
GO_0005615 | Cellular component | extracellular space |
GO_0031045 | Cellular component | dense core granule |
GO_0005737 | Cellular component | cytoplasm |
GO_0030133 | Cellular component | transport vesicle |
GO_0005515 | Molecular function | protein binding |
GO_0005184 | Molecular function | neuropeptide hormone activity |
Gene name | SPX |
Protein name | Spexin (NPQ) (Neuropeptide Q) (Spexin hormone) [Cleaved into: Spexin-1; Spexin-2 (NPQ 53-70)] Alternative protein C12orf39 Spexin hormone |
Synonyms | C12orf39 |
Description | FUNCTION: Plays a role as a central modulator of cardiovascular and renal function and nociception. Also plays a role in energy metabolism and storage. Inhibits adrenocortical cell proliferation with minor stimulation on corticosteroid release (By similarity). .; FUNCTION: [Spexin-1]: Acts as a ligand for galanin receptors GALR2 and GALR3 . Intracerebroventricular administration of the peptide induces an increase in arterial blood pressure, a decrease in both heart rate and renal excretion and delayed natriuresis. Intraventricular administration of the peptide induces antinociceptive activity. Also induces contraction of muscarinic-like stomach smooth muscles. Intraperitoneal administration of the peptide induces a reduction in food consumption and body weight. Inhibits long chain fatty acid uptake into adipocytes (By similarity). .; FUNCTION: [Spexin-2]: Intracerebroventricular administration of the peptide induces a decrease in heart rate, but no change in arterial pressure, and an increase in urine flow rate. Intraventricular administration of the peptide induces antinociceptive activity (By similarity). . |
Accessions | ENST00000546199.1 A0A3B3ISF3 F5GXE5 ENST00000535033.5 Q9BT56 L8E9B5 ENST00000256969.7 |